Project Details
| Status | Active |
|---|---|
| Effective start/end date | 8/25/21 → 8/25/24 |
Funding
- Novella Clinical, LLC (Prot #CAB-101)
- Cabaletta Bio, Inc. (Prot #CAB-101)
Prot #CAB-101: A Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects with Active, Anti-DSG3, Mucosal-Dominant Pemphigus Vulgaris
- Zhou, Alan (PD/PI)
Project: Research project